| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Freund’s incomplete adjuvant, one of the most popularly used adjuvant for cancer vaccines, has several adverse effects such as long term retention and an induction of inflammation at the injection site. We attempted to develop a next generation of transdermal vaccine for cancer treatment with no or low such adverse effects. We found that glycyrrhizin augmented vaccine-induced immune response with transdermal adjuvant, and the augmenting effect of glycyrrhizin was also observed in other synthetic HMGB1 inhibitors. Thus the effects are common to the HMGB1 inhibitors. In a therapeutic vaccine model, glycyrrhizin inhibited the growth of transplanted tumors. These findings might be valuable for further development of transdermal vaccines.
|
